1. The Third Hospital of Changsha, Changsha, Hunan 410035, China; 2. Hunan Provincial Corps Hospital, Chinese People's Armed Police Forces, Changsha, Hunan 410006, China
Abstract：Liver fibrosis is a pathological repair response to chronic liver disease, amd is characterized by the overaccumulation and reorganization of extracellular matrix. Liver biopsy is the gold standard for liver fibrosis determination. The use of non-invasive serum markers of liver fibrosis is particularly important due to the various limitations of this method, including patient injury and the risk of sampling errors. With intensive researches, some emerging biological markers are providing new clues to early predicting the severity of liver fibrosis in the clinical setting, assessing the effectiveness of treatment, improving the prognosis and finding out new therapeutic targets.
[1] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70( 1):151-171. [2] Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease[J]. Gut, 2017, 66(7):1321-1328. [3] Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury[J]. J Biol Chem, 2000, 275(4):2247-2250. [4] Avouac J, Degrave R, Vergneault H, et al. Risk of liver fibrosis induced by methotrexate and other rheumatoid arthritis medications according to the Fibrosis-4 Index[J]. Clin Exp Rheumatol, 2022(1):40. [5] Sohn W, Chang Y, Yong KC, et al. Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: a cohort study[J]. J Viral Hepatitis, 2022,29(1):69-77. [6] Yu S, Ericson M, Fanjul A, et al. Genome-wide CRISPR screening to identify drivers of TGF-beta-induced liver fibrosis in human hepatic stellate cells[J]. ACS Chem Biol, 2022,17(4):918-929. [7] 刘紫欣,袁宏博,陈娅斐,等. 细胞外基质的机械性质对肝癌发展的影响[J]. 河北工业大学学报, 2021,50(2):1-8. [8] Kulebina EA, Surkov AN, Fisenko AP, et al. The informative value of assessment of direct serum biomarkers for diagnosis of various stages of liver fibrosis in children[J]. Ru Pediatr J, 2021, 24(1):4-11. [9] Shizuma T. Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: a literature review[J]. World J Hepatol, 2018,10(2):254-266. [10] Meyerson C, Naini BV. Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors[J].Hum Pathol,2020,96:39-47. [11] Rockey D, Friedman S. Fibrosis regression after eradication of hepatitis C virus: from bench to bedside[J]. Gastroenterol, 2021, 160(5):1502-1520. [12] Robert S,Gicquel T,Victoni T, et al. Influence of inflammasome pathway activation in macrophages on the matrix metalloproteinase expression of human hepatic stellate cells[J]. Int Immunopharmcol,2019,72:12-20. [13] 苏静,胡以平. 肝纤维化发生及逆转途径的研究进展[J].癌变.畸变.突变,2022,34(3):242-246. [14] 李松鹏,景红艳. 甘胆酸(CG)在肝炎检测中的应用价值[J]. 中外医疗,2018,37(17):190-191,198. [15] 薛红,俞冲,顾玉玲,等. 血清肝纤维化指标、甘胆酸监测及肝脏硬度测定对慢性HBV感染的临床意义[J]. 南通大学学报(医学版) 2017,37(2):139-141. [16] Stefano JT, Guedes LV, Souza A, et al. Usefulness of collagen type IV in the detection of significant liver fibrosis innonalcoholic fatty liver disease[J]. Ann Hepatol, 2020, 20:100253. [17] Zheng YH,Cui JH,Gu J,et al. Diagnostic value of changes of serum adiponectin and cholylglycine levels in patients with nonalcoholic fatty liver fibrosis disease[J]. J Radioimmunol, 2012,25(5):553-555. [18] 李佳娜,郑瑞琦,李娜,等. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值[J].临床肝胆病杂志,2019,35(6):1361-1364. [19] Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases[J]. Cell Proliferat, 2018, 52(2):e12538. [20] Cao Z, Li Z, Liu Y, et al. A novel non-invasive Golgi protein 73 (GP73)-based model accurately diagnoses significant fibrosis in chronic liver disease[J]. J Hepatol, 2017, 66(1):S677. [21] Gatselis NK,Tornai T,Shums Z,et al. Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients[J]. World J Gastroenterol, 2020, 26(34):5130-5145. [22] Weiskirche R,Tacke F. Combining GP73 with liver stiffness measurements: a proof-of-concept for non-invasive fibrosis assessment in antiviral-naive HBV patients[J]. Liver Int, 2017, 37(11):1605-1607. [23] Pieczarkowski S, Kowalska-Deptuch K, Kwinta P, et al. Serum concentrations of fibrosis markers in children with inflammatory bowel disease[J]. Folia Med Cracov, 2020, 60(1):61-74. [24] Sobkowiak P, Narozna B, Wojsyk-Banaszak I, et al. Expression of proteins associated with airway fibrosis differs between children with allergic asthma and allergic rhinitis[J]. Int J Immunopathol Pharmacol, 2021, 35(2):91-98. [25] Wang SW, Hu MY, Qian YS,et al. CHI3L1 in the pathophysiology and diagnosis of liver diseases[J]. Biomed Pharmacother, 2020, 131:110680. [26] Huang Q, Wu J, Huang C, et al. A noninvasive diagnostic model for significant liver fibrosis in patients with chronic hepatitis B based on CHI3L1 and routine clinical indicators[J]. Ann Palliat Med, 2021,10(5):5509-5519. [27] Coriati A,Masse C,Menard A,et al. Neutrophils as a potential source of chitinase-3-like protein 1 in cystic fibrosis[J].Inflammation,2018,41(5):1631-1639. [28] Niu XM,Wang BY,Wang Y. Role of phosphatase and tensin homolog deleted on chromosome ten in a rat model of carbontetrachloride-induced liver fibrosis and the effect of qitonifying and blood-activating prescription[J]. J Clin Hepatol,2018,34(1):122-128. [29] Lagoutte P, Bettler E, Goff SVL, et al. Procollagen C-proteinase enhancer-1 (PCPE-1), a potential biomarker and therapeutic target for fibrosis[J]. Matrix Biol Plus, 2021, 11:100062. [30] Xi L,Jin QW,Yao QY,et al. Placental growth factor contributes to liver inflammation, angiogenesis, fibrosis in mice by promoting hepatic macrophage recruitment and activation[J].Front Immunol,2017,8:801. [31] 凌淳,李媛媛. 40岁以上HBeAg阴性慢性乙肝患者血清HBV DNA水平与肝纤维化的关系探讨[J].贵州医药,2022,46(1):27-28. [32] Freise C,Lee H, Chronowski C,et al. Alpha-single chains of collagen type VI inhibit the fibrogenic effects of triple helical collagen VI in hepatic stellate cells.[J].PLoS One,2021,16(9):e0254557. [33] Ueno T , Toyama C , Yoneyama T , et al. Impact of serum autotaxin level correlating with histological findings in biliary atresia[J]. J Pediatr Surg, 2021(10):1174-1178. [34] Shirabe K,Bekki Y,Gantumur D,et al.Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.[J].J Gastroenterol,2018,53(7):819-826. [35] 王伟,马玉萍,马海婷,等.血清M2BPGi联合MRI-DWI预测丙型肝炎患者肝纤维化的临床价值[J].实用医学杂志,2018,34(2):293-296,300. [36] Kim MY, Baik SK, Jang YO, et al. Serum hyaluronic acid level: correlation with quantitative measurement of hepatic fibrosis in a cirrhoticrat model[J]. Kr J Hepatol,2008,14(2):159-167. [37] 张先俊,徐莉芳,何忠良.原发性肝癌患者血清可溶性细胞间黏附分子-1的水平及其与肝纤维化的关系[J].解放军医药杂志,2017,29(3):31-34. [38] 粟春林. 血清巨噬细胞移动抑制因子、可溶型细胞间黏附分子-1及甲胎蛋白水平与慢性乙型肝炎患者肝纤维指标的关联性分析[J].实用医院临床杂志,2020,17(6):216-219. [39] Petrova T, Pesic J, Pardali K, et al. p38 MAPK signalling regulates cytokine production in IL-33 stimulated type 2 innate lymphoid cells[J]. Sci Rep, 2020,10(1):3479. [40] Cayrol C, Girard JP. Interleukin-33(IL-33): a nuclear cytokine from the IL-1 family[J]. Immunol Rev,2018,281(1):154-168. [41] Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis[J]. Front Immunol,2018,9:2432. [42] Peine M, Marek RM, Lshning M. IL-33 in T cell differentiation, function, and immune homeostasis[J]. Trends Immunol,2016,37(5):321-333. [43] Cayrol C, Girard JP. Interleukin-33(IL-33): a nuclear cytokine from the IL-1 family[J]. Immunol Rev,2018,281(1):154-168. [44] 朱海军,闫琼琼,陈巍,等. 腹腔注射IL-33抗体对CCl4诱导小鼠肝纤维化发病的作用[J].国际免疫学杂志,2019,42(3):290-295. [45] Zhang B, Meng FZ, Liu Y, et al. Inhibition of TGFβ1 accelerates regeneration of fibrotic rat liver elicited by a novel two-staged hepatectomy[J]. Theranostics, 2021, 11(10):4743-4758. [46] Zhang X, Xie X, Wang Y, et al. Interleukin-26 promotes the proliferation and activation of hepatic stellate cells to exacerbate liver fibrosis by the TGF-β1/Smad2 signaling pathway[J]. Int J Clin Exp Pathol, 2019, 12(12):4271-4279. [47] 何雪娟,任建立,张丽萍,等. TGF-β1基因多态性与肝纤维化易感性关系的meta分析[J].实用预防医学,2015,22(10):1195-1198. [48] Gong YF,Yang Y. Activation of Nrf2/AREs-mediated antioxidant signalling, and suppression of profibrotic TGF-β1/Smad3 pathway: a promising therapeutic strategy for hepatic fibrosis-A review[J]. Life Sci,2020,256:117909. [49] Lachowski D, Matellan C, Gopal S, et al. Substrate stiffness-driven membrane tension modulates vesicular trafficking via caveolin-1[J]. ACS Nano, 2022(3):16. [50] Shearer AM, Rana R, Austin K, et al. Targeting liver fibrosis with a cell-penetrating protease-activated receptor-2 (PAR2) pepducin[J]. J Biol Chem, 2016, 291(44):23188-23198. [51] Yan LK, Zhang X, Fu J, et al. Inhibition of the transient receptor potential vanilloid 3 channel attenuates carbon tetrachloride-induced hepatic fibrosis[J]. Biochem Biophys Res Commun, 2021, 558:86-93. [52] Loft A,Alfaro AJ,Schmidt SF,et al. Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication[J]. Cell Metab, 2021,33(8):1685-1700. [53] Huang Y,Deng X,Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis[J]. Exp Cell Res, 2017, 352(2):420-426. [54] Yue Z, Jiang Z, Bai R, et al. Disruption of myofibroblastic notch signaling attenuates liver fibrosis by modulating fibrosis progression and regression[J]. Int J Biol Sci, 2021, 17(9):2135-2146. [55] 荆菁华,史九波,安淑霞. miR-101在肝纤维化中表达及其与肝功能指标、炎性细胞因子、肝纤维化相关因子的相关性[J].实用预防医学,2021,28(1):102-105. [56] Weiskirchen R. Special issue on “cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis II”[J]. Cells, 2022, 11(15):2403.
2024, Vol. 31 
